Triangle firm’s Quantum Molecular drug design could revolutionize drug discovery
A Triangle-based biotech company may have the answer to both vastly reducing the cost of new drug discovery while also significantly speeding up the process of finding successful drug candidates to fight a wide range of indications, including cancer, central nervous system disorders and heart disease. The last week in June, RTP-based Cloud Pharmaceuticals, disclosed its first design of an active pro-drug for Crohn’s Disease and Inflammatory Bowel Disease in collaboration with the University of Florida (UF), and Ben-Gurion University of the Negev (BGU). A pro-drug only becomes a drug when it is activated in the body by a...
Read More
